echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 18 pharmaceutical companies among the Fortune China 500! China National Pharmaceutical Holdings led the way.

    18 pharmaceutical companies among the Fortune China 500! China National Pharmaceutical Holdings led the way.

    • Last Update: 2020-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network July 28th, July 27th, 2020 Fortune China's top 500 list officially unveiledNotably, there are 18 pharmaceutical companies on the listAmong them, China Pharmaceutical Holdings, Shanghai Pharmaceuticals, China Resources Pharmaceuticals, Kyushu Tong a total of 4 pharmaceutical companies shortlisted within 100, and Guang medicine Baiyunshan, Yunnan White Medicine, Hengrui Pharmaceuticals, Shi Pharma Group, Renfu Pharmaceutical and other companies are also on the listSupply chain platform construction to enhance core competitiveness from this list, China Pharmaceutical Holdings with revenue of 425.273 billion yuan ranked 22nd on the list, compared with last year, up three places, is the list of pharmaceutical enterprises in the highest revenue and profit enterprisesAccording to the annual report of Sinapharmaceutical Holdings, the company's operating income in 2019 was RMB52,046 million, compared with RMB43.122 billion in 2018, up 20.69 percent Year-on-YearNet profit attributable to shareholders of listed companies in 2019 was RMB1,271 million, compared with RMB1.210 billion in 2018, up 5.00% YoYKyushu Tong Pharmaceutical Group this year to improve the ranking of 6, successfully into the top 100According to the annual report data, Kyushu Tong achieved revenue of 99.497 billion yuan in 2019, up 14.19% YoY, and net profit of RMB1.727 billion, up 28.79% YoYAt the same time, we saw that the company achieved revenue of RMB27.173 billion in the first quarter of 2020, up 10.18% YoY, and net profit of RMB576 million, up 76.28% YoY, continuing the steady growth momentumAmong them, the company's traditional medical facilities realized sales of 35.910 billion yuan, up 20.77 percent year-on-year, retail pharmacies (wholesale business) realized sales of 26.55 0 billion yuan, up 17.65 percent year-on-year, downstream wholesalersales revenue of 31.687 billion yuan, up 8.06 percent year-on-year, b2B e-commerce/FBBC business sales of 11.854 billion yuan, up 30.20 percent year-on-yearLooking at these two enterprises are flowering, customer structure continued to improve, gross margin further increasedTake Kyushu Tong as an example, in the context of the implementation of the "two-vote system" policy, they have a national sales network, and through the modern logistics technology independent research and development and pharmaceutical logistics management system integration, the establishment of a unified national logistics storage system and supply chain system advantagesThey all rely on the channel logistics system to improve the efficiency of distribution of operating productsIn 2019, Kyushu General Agent Operating Goods Regulations 1013, achieved sales of 3.722 billion yuan, an increase of 26.93 percent year-on-year, sales gross margin of 15.91 percent, mainly due to the implementation of the "4 plus 7" band procurement, the original part of the hospital sales varieties to retail pharmacies sales accelerated the increase of the company's total agent varieties, and the general agent business high gross margin made a positive contribution to the company's rapid growthIn fact, these two commercial companies are promoting the construction of supply chain platform, through the advantages of efficient pharmaceutical warehousing logistics and distribution system, as well as the rich upstream and downstream pharmaceutical industry customer and product resources advantages, accelerate the docking of the Internet medical front end of the online Internet medical platform and the new establishment of the real hospital Internet hospital business, which has a positive significance for enhancing the core competitivenessInnovation is the driving force into the list of 18 pharmaceutical enterprises, 13 enterprises ranked higher than last year, of which the largest increase is Hengrui Pharmaceuticals, from 470 last year to 393 this year; In 2019, Ruikang Pharmaceuticals' profit was -927.8 million yuan, down 219.2% year-on-yearIt is worth noting that many of these companies are motivated by innovation Shanghai Pharma's 2019 financial results showed that net profit after net profit of RMB3.461 billion was RMB186.566 billion, up 17.27 percent and 30.49 percent, respectively, and operating cash flow inflows of RMB6,022 million, up 92.09 percent year-on-year In particular, Shanghai Pharma's industrial business achieved revenue of 23.490 billion yuan, up 20.70 percent year-on-year, with growth exceeding 20 percent for 11 consecutive quarters, and contributed 2,075 million yuan, up 24.50 percent year-on-year From its annual report, the large varieties of important areas are emerging, thanks to its emphasis on research and development investment In 2019, the company's total investment in research and development totaled 1.509 billion yuan, of which 1.350 billion yuan was spent, an increase of 27.22% year-on-year The company's innovative drug research and development pipeline has 15 innovative drugs (16 indications) in clinical research and clinical trial application stage Among them, 34.13% of the cost of independent research and development went to research and development of innovative drugs, and significant progress was made in stages Among them, SPH3127 completed the clinical phase II of all patients into the group, has started two new indications exploration research, Lei Gongto anti-wind-type phobia obtained clinical acquiescence, anti-AIDS indications started Phase II clinical trials, completed the first case of subjects into the group At the same time, the company through external cooperation and product introduction to further improve the pipeline layout This, from HengRui's annual report has also been fully demonstrated Hengrui Pharmaceuticals' 2019 revenue was RMB23,289 million, up 33.70% YoY Net profit attributable to shareholders of the parent company was RMB5.328 billion, up 31.05 percent year-on-year Net profit was RMB4,979 million, up 30.94 percent year-on-year By product, benefiting from the increase of the heavy new varieties such as Carelli bead seromto, injection yew alcohol (albumin binding type), and pyrith, the anti-tumor line grew the fastest, reaching 43.02 percent The anaesthetic line was affected by the right-hand metomihydrochloride, and the growth rate was slightly lower, at 18.35% The contrast agent was affected by the production capacity in mid-2019, with a growth rate of 38.97% Innovation is the foundation of their rapid growth and rise to the top of the list In 2020, Fortune China's top 500 pharmaceutical companies.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.